Mizuho Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and raises the price target from $30 to $39.
February 16, 2024 | 11:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Buy rating on EyePoint Pharmaceuticals and raises the price target from $30 to $39.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100